Stocks
Eli Lilly and CompanyLLY
NYSEHealthcarePharmaceuticals$985.08+0.80%
A major U.S. pharmaceutical manufacturer focused on developing and commercializing treatments for diabetes, obesity, oncology, immunology, and neuroscience. Its recent growth has been driven by blockbuster GLP-1 drugs for diabetes and weight loss, including Mounjaro and Zepbound, which have reshaped revenue expectations across the industry. Investors closely watch the company’s drug pipeline, clinical trial outcomes, and capacity expansion as demand for metabolic disease treatments accelerates.
Market Cap: $929.3B52W Range: $623.78 – $1133.95
Congressional Interest in Eli Lilly and Company (LLY)
15 members of Congress have disclosed 50 trades in Eli Lilly and Company (LLY), a Healthcare company. The buy/sell breakdown shows 17 purchases versus 33 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
15
Buys
17
Sells
33
Who in Congress Is Trading LLY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-11 | Dan Newhouse | sell | $1K – $15K |
| 2025-04-09 | Josh Gottheimer | sell | $1K – $15K |